Condition: Heart Failure · Coronary Arterial Disease · Sponsor: Pyatigorsk City Clinical Hospital Number 1
This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction \<50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).
This description comes directly from the study's public registry record.
Samson S. Badalyan, MD, PhD · +79614972949 · sambadalyan@mail.ru
Syune V. Markosyan, MD. · +79633876510 · ssm8883@gmail.com
Always discuss trial participation with your own doctor first.
| Pyatigorsk City Clinical Hospital Number 1 | Pyatigorsk, Stavropol Kray, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07601867